Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02159729 · ClinicalTrials.gov registry record · Phase 2
Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
A Phase 2 study, sponsored by Kythera Biopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 205
- Enrollment target
NCT02159729 is a Phase 2 study that has completed, run by Kythera Biopharmaceuticals. The registered enrollment target is 205 participants.
The verdict
NCT02159729, a Phase 2 study, has completed, sponsored by Kythera Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 205 participants
- Enrollment target
Study Summary
This was a long-term follow-up study of participants who completed Kythera-sponsored trials of ATX-101 (06-03, 07-07, 09-15)
Interventions
- DRUG Placebo
- DRUG ATX-101 (1 mg/cm^2)
- DRUG ATX-101 (2 mg/cm^2)
- DRUG ATX-101 (4 mg/cm^2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2009-02 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02159729
The ClinicalTrials.gov registry entry for NCT02159729 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kythera Biopharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02159729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02159729 about?
NCT02159729 is a clinical study titled "Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101". This was a long-term follow-up study of participants who completed Kythera-sponsored trials of ATX-101 (06-03, 07-07, 09-15)
What is the current status of trial NCT02159729?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 205 participants. The study started on 2009-02. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02159729?
The interventions under investigation include: Placebo (DRUG), ATX-101 (1 mg/cm^2) (DRUG), ATX-101 (2 mg/cm^2) (DRUG), ATX-101 (4 mg/cm^2) (DRUG).
Who is sponsoring clinical trial NCT02159729?
This trial is sponsored by Kythera Biopharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.